.png)
Tirzepatide belongs to a class of medications that act as dual GLP-1 and GIP receptor agonists. It's clinically proven to support weight loss, in combination with lifestyle changes. Patients have lost up to 21% of their body weight over time.
Tirzepatide is a GIP receptor and GLP-1 receptor agonist. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.
GLP-1 is a physiological regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. Both GIP receptors and GLP-1 receptors are found in areas of the brain involved in appetite regulation. Animal studies show that Tirzepatide distributes to and activates neurons in brain regions involved in regulation of appetite and food intake.
Tirzepatide lowers body weight with greater fat mass loss than lean mass loss. Tirzepatide decreases calorie intake. The effects are likely mediated by affecting appetite.
Tirzepatide stimulates insulin secretion in a glucose-dependent manner and reduces glucagon secretion. Tirzepatide increases insulin sensitivity, these effects can lead to a reduction of blood glucose.
Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time.
Tirzepatide mirrors two hormones your body naturally produces: GLP-1 and GIP. After eating, your body releases GLP-1 to signal your brain that you're full, while GIP helps regulate blood sugar and insulin response. Tirzepatide activates both pathways at once, sending a clearer, more consistent message of fullness to your brain, helping reset your body's biological set point so a lower weight becomes easier to maintain.
Many patients describe a phenomenon known as "food noise", a persistent, intrusive thoughts about food that make it hard to stick to healthy habits. In a US-based survey of people taking GLP-1, 62% of participants reported constant food-related thoughts before starting treatment, compared with only 16% while on GLP-1, a meaningful drop in the mental "noise" around eating. This effect appears to go beyond simple appetite suppression: researchers have observed that GLP-1 affects areas of the brain involved in appetite and reward-seeking behavior, including the hypothalamus, suggesting the medication may help quiet food-related thoughts at a neurological level, not just a physical one.
Tirzepatide is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:
-
Obesity
-
Some overweight adults who also have weight-related medical problems such moderate to severe obstructive sleep apnea (OSA) and obesity to improve their OSA.
-
Tirzepatide prescribed dose can be used once weekly at any time of the day.
Need to switch the day you take your dose? Just make sure you leave at least 3 days (72 hours) between injections.
If you miss a dose, take it as soon as you remember as long as it's within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip that dose entirely and simply resume on your regular scheduled day.If prescribed, you'll self-administer the medication as a subcutaneous injection in the stomach, thigh, or upper arm. Change (rotate) your injection site each week. You'll be given clear, step-by-step instructions to guide you through the process.
In rats, Tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Be aware of the potential risk for MTC with the use of Tirzepatide and inform your health practitioner of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).Tirzepatide is contraindicated in patients with:
-
A personal or family history of MTC or in patients with MEN 2.
-
Known serious hypersensitivity to Tirzepatide or any of the excipients in Tirzepatide. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Tirzepatide.
Tirzepatide adverse reactions include:
-
Gastrointestinal: nauseas, vomiting, diarrhoea, constipation, abdominal distension and/or discomfort, dyspepsia, reflux, flatulence, eructations.
-
Other warnings, adverse reactions and side effects: Injection site reactions, fatigue, hair loss (associated with weight reduction), dizziness, hypotension, acute pancreatitis, acute kidney injury due to volume depletion, hypoglycemia, dry mouth, Amylase and Lipase increase, diabetic retinopathy complications in patients with type 2 Diabetes Mellitus.
Drug Interactions: Tirzepatide can interact with other medications. Be sure to give your medical provider a full list of everything you're currently taking including prescriptions, over-the-counter drugs, vitamins, and herbal or dietary supplements. It can lower blood sugar levels if concomitant use with Insulin or an Insulin secretagogue (e.g. Sulfonylurea).
Tirzepatide delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with Tirzepatide.
Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with Tirzepatide.
Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with Tirzepatide and for 4 weeks after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected.
Specific populations use:
-
Pregnancy: Tirzepatide is not recommended during pregnancy and it should be to discontinued if trying to get pregnant or when a pregnancy is recognized.
-
Lactation: There are no available data on the effects of Tirzepatide on the breastfed infant or on milk production.
-
Pediatric Use: The safety and effectiveness of Tirzepatide have not been established in pediatric patients.
-
Renal Impairment: No dosage adjustment of Tirzepatide is recommended for patients with renal impairment.
-
Hepatic Impairment: No dosage adjustment of Tirzepatide is recommended for patients with hepatic impairment.
Overdose: In the event of an overdose, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.
Tirzepatide should not be used with other GLP-1 medications including Semaglutide, Mounjaro, Zepbound, Wegovy, Ozempic, Saxenda.
​
-
Wegovy and Zepbound are all FDA-approved for weight loss, while Mounjaro and Ozempic is FDA-approved for type 2 diabetes, though it can be prescribed off-label for weight loss when appropriate.
The key difference between these medications comes down to their active ingredient. Non-branded Semaglutide, Ozempic and Wegovy all contain Semaglutide as an active ingredient, while non-branded Tirzepatide, Mounjaro, and Zepbound contain Tirzepatide. Tirzepatide works differently, it has dual action, activating both GLP-1 and GIP receptors, while Semaglutide activates only the GLP-1 receptor. Despite this difference, both medications work similarly in helping curb hunger and regulate appetite, so you feel fuller, faster and for longer.
* GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1.
(1) Gilbert O, Gulati M, Gluckman TJ, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health. J Am Coll Cardiol. Published online June 2025.
** Note: Not available in all 50 states. Prescription required. Tirzepatide is prescribed based on what the health provider determines is medically appropriate for you.
* GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1.
(1) Gilbert O, Gulati M, Gluckman TJ, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health. J Am Coll Cardiol. Published online June 2025.
** Note: Not available in all 50 states. Prescription required. Tirzepatide is prescribed based on what the health provider determines is medically appropriate for you.
Weight Loss & Metabolic Health
The Vitaria Difference
Not just treatment. A more complete way to feel well. A body you live in, not fight with.
Dual GLP-1-GIP medications such as Tirzepatide stabilise blood glucose levels in the body and work with your hunger signals, not against them, changing not just your weight, but your relationship with food entirely. The result isn't just weight loss. It's feeling like yourself again.
.png)
NAD +
Your plan includes :
-
Initial provider evaluation & ongoing clinical oversight
-
Medication & Shipping cost
-
Direct access to the health care providers whenever you need through the patient portal
-
Medication shipped discreetly to your door
-
​HSA/FSA eligible
Your plan includes :
Steps to see if you are eligible
Weight loss treatment access in only 3 steps
1. Fill out a brief intake form about your health
2. A health provider will review your information and reach out within 24 hours
3. If you're approved, your medicine gets sent to your door
Other Weight Loss & Metabolic Health Treatment Options
.png)
.png)
.png)
.png)
.png)
Our treatment approach of proven therapies with lifestyle guidance to help you keep the weight off for good
Metabolic Support
First, the weight starts to come off
The treatment works with your body to target and address what's actually driving the weight gain in the first place.
Reduce cravings
It quiets the constant mental noise around food, giving you the space to build lasting healthy habits that help keep the weight off.
Time for exercise reset
Your metabolism does respond to things you do. Building muscle through resistance training and adding daily movement is important while using GLP-1s
Build long lasting nutrition habits
Develop sustainable eating patterns rooted in adequate protein, fiber and diverse food groups for long-term health.
In the pancreas, controls de release of glucagon
Glucagon is a hormone that tells the liver to release more sugar into the blood, both while fasting and after meals.
Slows down digestion
It slows how quickly food leaves the stomach and reaches the small intestine. This softens blood sugar spikes after eating and helps people feel full sooner, but it's also why nausea is common, especially when starting the medication or increasing the dose.
Curbs appetite, drives weight loss
In the brain (the main reason people lose weight), it acts on appetite-control centers (and related nerve pathways), which reduces hunger and how much people eat.
Boosts insulin, but only when blood sugar levels are high
Signals the pancreas to release more insulin after meals, but only when blood sugar level is actually elevated. This is called the "incretin effect," and it's why the risk of low blood sugar stays low. At the cellular level, the drug attaches to a receptor that triggers an internal chain reaction in pancreatic cells, ultimately prompting them to release insulin and supporting the health of those cells.
Tirzepatide effects explained...
The mechanisms involved in how Tirzepatide helps with weight management and glucose control
